From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...

Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. | Eli Lilly is making investments ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

Veeva is paying approximately $100 million to acquire Ostro, according to this week’s announcement, comprising a combination ...

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

During a quarterly conference call, executives from Legend Biotech showed little concern for a new threat to its lone commercial product, multiple myeloma CAR-T Carvykti. | During a quarterly ...

Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...